Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Am Acad Dermatol ; 56(1): 88-90, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17190624

RESUMEN

We tested the hypothesis that contact allergy plays a role in chronic urticaria, and included the Italian series of patch tests in the diagnostic workup. Of 121 patients with chronic urticaria, 50 (41%) tested positive to contact allergens. In all patients, avoidance measures led to a complete remission within 1 month. We suggest that testing for contact sensitization can be helpful in the management of chronic urticaria.


Asunto(s)
Alérgenos , Dermatitis Alérgica por Contacto/complicaciones , Urticaria/etiología , Adolescente , Adulto , Anciano , Alérgenos/inmunología , Enfermedad Crónica , Cosméticos/efectos adversos , Dermatitis Alérgica por Contacto/diagnóstico , Dermatitis Alérgica por Contacto/dietoterapia , Dermatitis Alérgica por Contacto/inmunología , Dermatitis Alérgica por Contacto/terapia , Detergentes/efectos adversos , Dieta/efectos adversos , Femenino , Artículos Domésticos , Humanos , Masculino , Persona de Mediana Edad , Níquel/efectos adversos , Pruebas del Parche , Inducción de Remisión , Urticaria/dietoterapia , Urticaria/inmunología , Urticaria/terapia
2.
Int Arch Allergy Immunol ; 135(2): 143-7, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15345913

RESUMEN

BACKGROUND: Desloratadine (DL) and levocetirizine (LCZ) are the newest commercialized antihistamines. Pharmacokinetics, pharmacodynamics and clinical data are available for both drugs, but there is to date no direct comparison involving the nose and skin at the same time. We compared the effects of a single dose of the two drugs in the nose and skin over 24 h. METHODS: Twenty-three patients with symptomatic allergic rhinitis were enrolled in a randomized double-blind crossover administration of DL and LCZ. The histamine-induced wheal and flare was measured at baseline and 2 and 24 h after dosing. A reflective total symptom score (rTSS) for the previous 24 h was assessed before and after each dose. An instant symptom score was also measured at various time points after each drug. RESULTS: LCZ provided greater inhibition of the flare at 2 h (p = 0.05) and at 24 h (p = 0.007) and greater inhibition of the wheal only at 2 h (p = 0.02). The decrease in wheal and flare was significant versus baseline (p = 0.007) with both drugs. The rTSS of the previous 24 h decreased significantly with both LCZ (11.53 vs. 8.0; p < 0.05) and DL (11.3 vs. 7.9; p < 0.05). The instant TSS progressively decreased in parallel with both drugs, but a difference in favor of LCZ was seen 2 h after dosing. CONCLUSIONS: Single doses of DL and LCZ had a comparable effect on nasal symptoms, but LCZ was faster and displayed a greater effect on histamine wheal.


Asunto(s)
Cetirizina/uso terapéutico , Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Loratadina/análogos & derivados , Loratadina/uso terapéutico , Nariz/efectos de los fármacos , Piperazinas/uso terapéutico , Rinitis/tratamiento farmacológico , Piel/efectos de los fármacos , Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas Cutáneas , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA